Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Principles and general themes
-
1. Oncolytic viruses: strategies, applications and challenges
- Dr. Stephen J. Russell
-
2. Directed evolution of AAV delivery systems for clinical gene therapy
- Prof. David Schaffer
-
6. The host response: adaptive immune response to viral vector delivery
- Prof. Roland W. Herzog
-
7. Gene therapy and virotherapy in the treatment of cancer
- Prof. Leonard Seymour
-
8. Gene therapy for the muscular dystrophies
- Prof. Jeff Chamberlain
- Major gene transfer platforms and gene therapy strategies
-
9. Gammaretroviral vectors: biology, design and applications
- Prof. Axel Schambach
-
13. Surface-mediated targeting of lentiviral vectors
- Prof. Dr. Christian Buchholz
-
14. Gene transfer and gene therapy
- Dr. David A. Williams
-
15. Tracking vector insertion sites to explore the biology of transduced cells in vivo
- Prof. Dr. Christof Von Kalle
-
16. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
17. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
20. Gene therapy for hemophilia
- Prof. Katherine High
- New technologies for sequence-specific editing of gene expression
-
21. Helper-dependent adenoviral vectors for gene therapy
- Prof. Nicola Brunetti-Pierri
-
22. HSV vectors: approaches to the treatment of chronic pain
- Prof. Joseph C. Glorioso
- Archived Lectures *These may not cover the latest advances in the field
-
23. RNAi for neurological diseases
- Prof. Beverly L. Davidson
-
24. Directed evolution of novel adeno-associated viral vectors for gene therapy
- Prof. David Schaffer
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosure
- Oncolytic virotherapy
- Any virus can be adapted
- Key considerations in oncolytic virotherapy
- What can we learn from studies of natural virus pathogenesis?
- Poliovirus pathogenesis in humans and transgenic mice
- Oncolytic virus examples
- Measles pathogenesis
- Origin of MV-NIS, a safe, trackable oncolytic measles virus
- Durable complete remission of disseminated cancer after a single MV-NIS infusion
- Anti-measles antibodies negate the efficacy of intravenous MV-NIS
- Targeting: Receptor-specific measles viruses displaying cell-targeting ligands
- Targeting an MHC-peptide complex with a measles virus displaying scTCR
- Discriminating receptor density on target cells using measles viruses
- Stealthed, targeted, armed measles virus (MV-STAR)
- Oncolytic virus examples: Vesicular stomatitis virus
- Vesicular stomatitis virus
- First-in-human clinical trial of VSV (VSV-IFNβ) as intratumoral therapy
- Case details: Tumor lysis after intratumoral VSV-IFNβ
- Postulated MOA for intratumoral VSV
- Intravenous VSV-IFNβ-NIS
- Intravenous VSV-IFNβ-NIS: Higher doses are more effective
- VSV-IFNβ-NIS canine lymphoma trial
- Human trial of intravenous VSV-IFNβ-NIS in hematologic malignancies
- Voyager-V1 is active after a single infusion
- Postulated MOA for intravenous VSV-IFNβ-NIS in T cell lymphoma
- Combination therapy with VSV-mIFNβ-NIS + αPD1 + αCTLA4 antibodies
- VSV-IFNβ-NIS in human subjects: Experience to date
- Oncolytic virus examples: Picornaviruses
- Infectious picornavirus RNA
- Coxsackievirus A21
- Oncolytic virus examples: Herpesviruses
- Status of the OV field Q1 2023
- Boosting the clinical efficacy of T-VEC via combination therapy
- Combining herpesviruses (HSV+CMV) as an alternative approach for boosting OV efficacy
- HSV1-IL12 + mCMV are synergistic in a bilateral B16-F10-nectin1 model
- Taking intratumoral OVs to the next level
- CMV to convert infected cells into lentiviral vector factories
- Envisioned strategy to use CMV as an oncolytic vector that also delivers lentiviral CAR-T therapy
- Conclusions
- Acknowledgments
Topics Covered
- Measles
- Vesicular stomatitis virus
- Picornavirus
- Herpesvirus
- Coxsackievirus
- Cytomegalovirus
- Modified Measles Virus (MV-NIS)
- T cell lymphoma
- Clinical trials
- Voyager-V1
- Talimogene laherparepvec (T-VEC)
Talk Citation
Russell, S.J. (2023, September 28). Oncolytic viruses: strategies, applications and challenges [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 15, 2024, from https://doi.org/10.69645/LNUY8580.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Russell is a cofounder, shareholder and CEO of Vyriad, a company that is developing and commercializing targeted genetic medicines, including oncolytic virus therapies.
A selection of talks on Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, I'm Stephen
Russell, CEO of Vyriad.
The title of my talk today is
Oncolytic Viruses Strategies,
Applications and Challenges.
0:17
By way of disclosure,
I am a co founder, shareholder,
and the CEO of Vyriad which
is a company developing and
commercializing targeted
genetic medicines
including oncolytic
virus therapies.
0:32
Let's get into oncolytic
virus therapy.
This slide illustrates
the two stage model
of oncolytic virus
therapy in which
the virus infects
the tumor spreads
locally and causes tube cell
killing with release of
tumor antigens which in turn
are picked up by
the immune system
and drive the amplification of
the anti tumor immune
response which brings
about longer term control of
distant, uninfected tumors.
1:06
Virtually any virus
can theoretically be
adapted or engineered to be
an effective oncolytic agent.
There is a vast universe
of different viruses
out there with DNA
or RNA genomes with
single or double
stranded nucleic acid
encapsidated and with in
the case of RNA viruses,
positive sense or negative
sense RNA genomes.
This is truly a vast
untapped bio resource
for future development in
the field of oncolytic
virus therapy.